Please ensure Javascript is enabled for purposes of website accessibility

Where to Invest $10,000 Right Now

By Adria Cimino – Sep 4, 2020 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These companies have proven themselves in recent, difficult times.

This year's market crash was a great reminder of how important it is to have solid companies in your investment portfolio. In good times, you're able to count on their performance. And when bad times roll around, you can have confidence they will manage the crisis and rebound quickly.

These solid companies often aren't the cheapest in the market, but they are well worth the investment because of their track record and future revenue growth prospects. Here, I've chosen three that fit the bill. Investment in all of them will offer you diversification across three industries.

So, if you have $10,000 to invest, consider these top stocks.

A woman hugs a piggy bank with money tucked in the slot.

Image source: Getty Images.

1. Amazon

Amazon (AMZN -0.54%) shares have been unstoppable, with gains of 84% so far this year. It's easy to understand why. While most retailers struggled through the earlier stages of the coronavirus outbreak, Amazon had to hire to keep up with demand. In the second-quarter earnings report, Amazon said it created 175,000 jobs since March -- and for good reason. Sales in the quarter climbed 40% to $88.9 billion, and net income doubled to $5.2 billion. Online grocery -- an area where Amazon and Walmart (WMT -0.93%) have been fighting for dominance -- saw gains too, with sales tripling in the quarter.

Some might ask if Amazon's fortunes will continue when the coronavirus crisis wanes. While sales increases may not be as steep, it's clear the positive trend will continue. First, some consumers may not return to pre-crisis shopping habits. They may prefer the convenience of online shopping and still might want to avoid crowds. Amazon's pre-crisis performance is another guide: The retailer's annual revenue has been climbing for more than a decade.

Currently trading at 130 times trailing 12-month earnings, Amazon's stock isn't cheap. But the company's variety of businesses -- Amazon Web Services, devices, entertainment, online shopping -- and its continued growth trend make it worth the bet.

2. Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX -1.12%), a leader in the cystic fibrosis treatment market, offers investors a buying opportunity today. The biotech is down 11% from an all-time high reached in July. Wall Street analysts predict that the stock will gain 14% over the next 12 months. Vertex stock trades at 34 times trailing 12-month earnings -- close to its lowest point this year but still higher than some biotech companies. Why do I expect share gains to resume? The answer is simple -- revenue power.

While many companies have been withdrawing guidance or revising lower, Vertex has done the opposite. The company predicted total full-year product revenue of $5.7 billion to $5.9 billion from its earlier range of $5.3 billion to $5.6 billion. Vertex beat analysts' earnings estimates for the past four quarters and has quadrupled annual revenue to more than $4 billion over the past five years. Trikafta, its newest cystic fibrosis drug, drove a 62% gain in total product revenue in the second quarter. The U.S. Food and Drug Administration approved the treatment last fall, and the European Commission approved it in August. Why is Trikafta such a big deal? Because it has the potential to treat up to 90% of people with the disease.

While cystic fibrosis treatments offer revenue well into the future, Vertex has programs in the pipeline in other areas too, such as blood disorders and pain. The company is also working with CRISPR Therapeutics (CRSP 0.97%) on gene editing therapy, which involves altering genetic material that causes disease.

3. McDonald's

The coronavirus outbreak has hurt McDonald's (MCD -1.81%), as it has been forced to close dining rooms in the U.S. and rely on just drive-thru and delivery services in many areas and closed half of its restaurants internationally. Prior to the crisis, about 70% of orders were taken in restaurants in the company's larger international markets. The fast-food giant reported a 23.9% drop in global comparable sales in the second quarter. Still, the company managed to maintain profitability, reporting $483.8 million in net income.

There are a few more positive elements that make me optimistic about the future of McDonald's. Brand strength is one. Many of us think of McDonald's first when it comes to fast food. Now, McDonald's plans on ensuring that as it aims to invest its "sizable marketing war chest" during the third and fourth quarters. I also like the fact that McDonald's says it is focusing on digital orders, drive-thru, and delivery. Even once the coronavirus crisis subsides, consumers are likely to prefer avoiding contact when possible. About 95% of McDonald's U.S. locations offer drive-thru. In large international markets, that number is 70%.

Dividend is another reason to invest in McDonald's for the long term. The company has increased its quarterly dividend ever since it first started paying one in 1976. And in the second-quarter earnings call, the company said paying dividends remains one of its priorities.

McDonald's is trading at more than 33 times trailing 12-month earnings, its highest this year by that measure. Shares have rebounded from earlier declines and now are up about 8% for the year. I don't expect McDonald's revenue to recover immediately. But investors who pick up the stock now will be -- to use one of the company's old slogans -- "lovin' it" in the long term.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino owns shares of Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Amazon and CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

McDonald's Corporation Stock Quote
McDonald's Corporation
MCD
$234.75 (-1.81%) $-4.34
Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$120.30 (-0.54%) $0.65
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$298.63 (-1.12%) $-3.39
Walmart Stock Quote
Walmart
WMT
$131.68 (-0.93%) $-1.24
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$65.26 (0.97%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.